Business Context and Reporting Period
Company: Milestone Scientific Inc. (MLSS)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2024
Business Overview: Milestone Scientific develops and commercializes computer-controlled anesthetic delivery devices for dental and medical use. Key products include the STA Single Tooth Anesthesia System (dental) and the CompuFlo Epidural Computer Controlled Anesthesia System (medical). The company relies on third-party manufacturers and utilizes an E-Commerce platform for a significant portion of its U.S. dental sales.
Key Financial Metrics
| Metric | 2024 | 2023 |
|---|---|---|
| Net Product Sales | $8,629,928 | $9,827,444 |
| Gross Profit | $6,434,588 | $6,792,612 |
| Gross Margin | 74.6% | 69.1% |
| Operating Loss | $(6,756,957) | $(7,106,474) |
| Net Loss | $(4,713,597) | $(6,980,947) |
| Cash Used in Operating Activities | $(2,919,875) | $(5,326,129) |
| Cash and Cash Equivalents (Year End) | $3,258,058 | $2,977,713 |
| Working Capital | $5,542,427 | $7,717,756 |
Note: The 2024 Net Loss includes a one-time gain of $1,983,095 from the sale of New Jersey net operating losses (NOLs).
Material Changes vs. Prior Period
- Revenue Decline: Total net sales decreased by approximately $1.2 million (12.2%) year-over-year.
- Dental Segment: Sales dropped $1.23 million, driven by a $756,000 decrease in international revenue and the termination of non-exclusive distributor agreements in the U.S. in late 2023.
- Medical Segment: Sales increased by $36,820, reflecting early adoption of the CompuFlo Epidural System.
- Improved Gross Margin: Gross margin improved to 74.6% from 69.1%, primarily due to higher margins from the E-Commerce platform offsetting lower international sales volume.
- Expense Reduction: Selling, general, and administrative (SG&A) expenses decreased by $840,000, largely due to reduced employee salaries and benefits ($654,000) and lower warehousing and marketing costs.
- Operating Loss Narrowing: The operating loss decreased by $350,000 compared to 2023, aided by the expense reductions and the NOL sale gain.
Outlook, Risks, and Management Commentary
- Going Concern: The company has incurred significant losses since inception ($128.1 million accumulated deficit). Management states that existing cash ($3.3 million) combined with a $800,000 related-party note financing received in April 2025 is sufficient to fund operations for the next 12 months, alleviating substantial doubt about the company's ability to continue as a going concern.
- Strategic Shifts: Management has decided to delay all research and development on the next-generation STA Single Tooth Anesthesia System to conserve cash. Focus remains on expanding the CompuFlo medical product line and E-Commerce dental sales.
- Regulatory Milestones: In 2024, the company received Medicare Part B physician price assignments in multiple jurisdictions (Florida, Delaware, DC, Maryland, NJ, PA, and others) for the CompuFlo system, facilitating reimbursement. It also received regulatory approval in Brazil.
- Key Risks:
- Liquidity: Continued need for additional capital to fund operations and commercialization efforts.
- Supply Chain: Reliance on third-party manufacturers (including a sole manufacturer in China for handpieces) without long-term supply commitments.
- Market Acceptance: Uncertainty regarding physician adoption of the CompuFlo Epidural System.
- Leadership Transition: CEO Arjan Haverhals retired in December 2024; Neal Goldman serves as Interim CEO.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $3.3 million cash balance and the $800,000 related-party note to cover operating burn rates through 2025.
- Revenue Concentration: Assess the impact of the 60% reliance on E-Commerce sales and the loss of major U.S. distributors (e.g., Henry Schein) on future growth.
- Medical Adoption: Monitor the conversion rate of Medicare price assignments into actual sales volume for the CompuFlo system.
- Supply Chain Stability: Confirm the status of manufacturing relationships, particularly with the sole Chinese handpiece supplier, given the lack of long-term contracts.
- Related Party Transactions: Review the terms of the April 2025 financing notes issued to directors and the ongoing royalty/consulting agreements with key insiders.